Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series

Highlights • Patients with somatic EGFR mutations are eligible for tyrosine kinase inhibitors. • Circulating tumor DNA (ctDNA) can be used to identify EGFR mutations. • Quantitative ctDNA assessment has the potential to assess therapeutic response.

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-06, Vol.108, p.22-28
Main Authors: Tchekmedyian, Nishan, Mudad, Raja, Blanco, Fernando F, Raymond, Victoria M, Garst, Jordan, Erlander, Mark G, Haura, Eric, Berz, David
Format: Article
Language:English
Subjects:
Alleles
Amino Acid Substitution
Antineoplastic Agents - therapeutic use
Biopsy
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - mortality
Circulating Tumor DNA
DNA, Neoplasm - urine
EGFR
Female
Hematology, Oncology and Palliative Medicine
Humans
Longitudinal monitoring
Longitudinal Studies
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Magnetic Resonance Imaging - methods
Middle Aged
Mutation
Non-small cell lung cancer
Protein Kinase Inhibitors - therapeutic use
Pulmonary/Respiratory
Receptor, Epidermal Growth Factor - genetics
Systemic mutation burden
Tomography, X-Ray Computed
Treatment Outcome
Tyrosine kinase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Patients with somatic EGFR mutations are eligible for tyrosine kinase inhibitors. • Circulating tumor DNA (ctDNA) can be used to identify EGFR mutations. • Quantitative ctDNA assessment has the potential to assess therapeutic response.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2017.02.010